XML 35 R23.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment reporting (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Segment Reporting [Abstract] |
Schedule of Segment Reporting Information, by Segment | The table below is a summary of the significant segment expenses (in thousands) provided to the Company’s CODM on a regular basis:
|  | Three Months Ended September 30, | Nine Months Ended September 30,
|  | 2025 |  | 2024 | 2025 |  | 2024
Drug creation programs and platform (1) |  | $ | 5,669 |  |  | $ | 4,144 |  | $ | 14,963 |  |  | $ | 11,635 |
External preclinical and clinical development (2) |  | 3,606 |  |  | 2,852 |  | 11,660 |  |  | 5,178 |
Personnel (3) |  | 10,488 |  |  | 9,813 |  | 30,638 |  |  | 29,137 |
Stock-based compensation |  | 4,396 |  |  | 5,508 |  | 14,093 |  |  | 14,401 |
General & administrative |  | 3,531 |  |  | 3,799 |  | 11,158 |  |  | 11,352 |
Asset and goodwill impairment |  | — |  |  | 1,125 |  | — |  |  | 1,125 |
Depreciation and amortization |  | 2,842 |  |  | 3,355 |  | 8,914 |  |  | 10,155 |
Total operating expenses |  | $ | 30,532 |  |  | $ | 30,596 |  | $ | 91,426 |  |  | $ | 82,983 |
(1) “Drug creation programs and platform” consists of research and development costs incurred related to the Company’s internally developed programs and drug creation partnership programs for activities prior to the nomination of a development candidate and the continued development of the Company’s Integrated Drug Creation platform. (2) “External preclinical and clinical development” expense consists of external costs incurred following the Company’s nomination of a development candidate, including all subsequent contract research services, contract manufacturing, consulting fees, and other external costs related to preclinical and clinical development. (3) “Personnel” expense consists of all employee wages, taxes, benefits, other employee related costs.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration